<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Clostridium Difficile Infection</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->6/24/2011</div></div><div class="card__content"><h1 id="clostridium-difficile-infection-cdi-">Clostridium Difficile Infection (CDI)</h1>
<h2 id="treatment">Treatment</h2>
<table>
<thead>
<tr>
<th>Clinical Category</th>
<th>Presentation</th>
<th>Treatment</th>
</tr>
</thead>
<tbody><tr>
<td>1st episode, mild-moderate severity</td>
<td>| <span class="drug">Metronidazole</span> 500 mg PO TID x 10-14 days</td>
<td></td>
</tr>
<tr>
<td>1st episode, severe</td>
<td>Serum WBC ≥15k or creatinine &gt; 1.5x baseline</td>
<td><span class="drug">Vancomycin</span> 125 mg PO QID x 10-14 days</td>
</tr>
<tr>
<td>1st episode, severe,complicated</td>
<td>Hypotension, shock ileus, or megacolon</td>
<td><span class="drug">Vancomycin</span> 500 mg QID PO/NG (PR if ileus) PLUS <span class="drug">Metronidazole</span> 500 mg IV q8h</span></td>
</tr>
<tr>
<td>First recurrence</td>
<td>| Same as for 1st episode (because minimal resistance)</td>
<td></td>
</tr>
<tr>
<td>Second and more recurrences</td>
<td>| <span class="drug">Vancomycin</span> PO in tapered or pulsed regimen. Avoid <span class="drug">metronidazole</span> overuse because of neurotoxicity.</td>
<td></td>
</tr>
</tbody></table>
<h2 id="background">Background</h2>
<h3 id="definition-of-clostridium-difficile-infection-cdi-">Definition of <em>Clostridium difficile</em> infection (CDI)</h3>
<ul>
<li>Presence of diarrhea (3 unformed stools in ≤24 hours)</li>
<li>Stool test positive for <em>C. difficile</em> or its toxins, or colonoscopic findings of pseudomembranous colitis</li>
</ul>
<h3 id="epidemiology">Epidemiology</h3>
<ul>
<li>Accounts for 20-30% of all antibiotic-associated diarrhea</li>
<li>Most common cause of infectious diarrhea in healthcare settings</li>
</ul>
<h3 id="transmission">Transmission</h3>
<ul>
<li>Fecal-oral route</li>
<li>Median time from exposure to C. difficile to diarrhea symptoms = 2-3 days</li>
</ul>
<h3 id="risk-factors-to-develop-cdi">Risk factors to develop CDI</h3>
<ul>
<li>Age &ge; 65 years</li>
<li>Duration of hospitalization</li>
<li>Exposure to antibiotics (almost every Abx has been assoc with CDI – not just <span class="drug">clindamycin</span>)<ul>
<li>96% have received abx within 14 days before diarrhea onset </li>
</ul>
</li>
<li>Cancer chemotherapy</li>
<li>HIV</li>
<li>GI surgery or manipulation of GI tract (i.e. tube feeding)</li>
</ul>
<h3 id="clinical-presentation">Clinical presentation</h3>
<ul>
<li>Diarrhea may have mucous or occult blood</li>
</ul>
<h3 id="recurrence-rates">Recurrence rates</h3>
<ul>
<li>20% (typically within 4 weeks), despite <span class="drug">metronidazole</span> or <span class="drug">vancomycin</span> treatment (<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18971494">Kelly et al., NEJM, 2008</a>)</li>
</ul>
<h2 id="complications">Complications</h2>
<ul>
<li>Bowel perforation</li>
<li>Dehydration</li>
<li>Electrolyte imbalance </li>
<li>Hypoalbuminemia</li>
<li>Hypotension</li>
<li>Renal failure</li>
<li>SIRS, sepsis</li>
<li>Toxic megacolon</li>
<li>Death</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li>Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by SHEA and IDSA. Infect Control Hosp Epidemiol. 2010; 31(5):431-55. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20307191">PubMed</a>]</li>
<li>Kelly CP, LaMont JT.Clostridium difficile--more difficult than ever.N Engl J Med. 2008 Oct 30;359(18):1932-40. doi: 10.1056/NEJMra0707500. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18971494">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"cdiff","title":"Clostridium Difficile Infection","authors":["Michelle Lin, MD"],"categories":[{"slug":"infectious-disease","name":"Infectious Disease"}],"created":"2011/06/24","updated":null,"body":"\n# Clostridium Difficile Infection (CDI)\n\n## Treatment\n\n| Clinical Category                   | Presentation                                 | Treatment                                                                                                                                             |\n| ----------------------------------- | -------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------- |\n| 1st episode, mild-moderate severity |                                              | \u003cspan class=\"drug\"\u003eMetronidazole\u003c/span\u003e 500 mg PO TID x 10-14 days                                                                                    |\n| 1st episode, severe                 | Serum WBC ≥15k or creatinine \u003e 1.5x baseline | \u003cspan class=\"drug\"\u003eVancomycin\u003c/span\u003e 125 mg PO QID x 10-14 days                                                                                       |\n| 1st episode, severe,complicated     | Hypotension, shock ileus, or megacolon       | \u003cspan class=\"drug\"\u003eVancomycin\u003c/span\u003e 500 mg QID PO/NG (PR if ileus) PLUS \u003cspan class=\"drug\"\u003eMetronidazole\u003c/span\u003e 500 mg IV q8h\u003c/span\u003e                 |\n| First recurrence                    |                                              | Same as for 1st episode (because minimal resistance)                                                                                                  |\n| Second and more recurrences         |                                              | \u003cspan class=\"drug\"\u003eVancomycin\u003c/span\u003e PO in tapered or pulsed regimen. Avoid \u003cspan class=\"drug\"\u003emetronidazole\u003c/span\u003e overuse because of neurotoxicity. |\n\n## Background\n\n### Definition of _Clostridium difficile_ infection (CDI)\n\n- Presence of diarrhea (3 unformed stools in ≤24 hours)\n- Stool test positive for _C. difficile_ or its toxins, or colonoscopic findings of pseudomembranous colitis\n\n### Epidemiology\n\n- Accounts for 20-30% of all antibiotic-associated diarrhea\n- Most common cause of infectious diarrhea in healthcare settings\n\n### Transmission\n\n- Fecal-oral route\n- Median time from exposure to C. difficile to diarrhea symptoms = 2-3 days\n\n### Risk factors to develop CDI\n\n- Age \u0026ge; 65 years\n- Duration of hospitalization\n- Exposure to antibiotics (almost every Abx has been assoc with CDI – not just \u003cspan class=\"drug\"\u003eclindamycin\u003c/span\u003e)\n  - 96% have received abx within 14 days before diarrhea onset \n- Cancer chemotherapy\n- HIV\n- GI surgery or manipulation of GI tract (i.e. tube feeding)\n\n### Clinical presentation\n\n- Diarrhea may have mucous or occult blood\n\n### Recurrence rates\n\n- 20% (typically within 4 weeks), despite \u003cspan class=\"drug\"\u003emetronidazole\u003c/span\u003e or \u003cspan class=\"drug\"\u003evancomycin\u003c/span\u003e treatment ([Kelly et al., NEJM, 2008](https://www.ncbi.nlm.nih.gov/pubmed/?term=18971494))\n\n## Complications\n\n- Bowel perforation\n- Dehydration\n- Electrolyte imbalance \n- Hypoalbuminemia\n- Hypotension\n- Renal failure\n- SIRS, sepsis\n- Toxic megacolon\n- Death\n\n## References\n\n- Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by SHEA and IDSA. Infect Control Hosp Epidemiol. 2010; 31(5):431-55. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20307191)]\n- Kelly CP, LaMont JT.Clostridium difficile--more difficult than ever.N Engl J Med. 2008 Oct 30;359(18):1932-40. doi: 10.1056/NEJMra0707500. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18971494)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"cdiff"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>